Remedy Robotics Raises $62M Series B to Advance AI Cardiovascular Care

What happened
Remedy Robotics announced on November 16, 2026 that it raised $62 million in Series B funding. The funding will support the development and clinical trials of its N1 robotic platform, which uses AI to assist with cardiovascular procedures. The company is working with the University of California to conduct pivotal clinical trials and pursue FDA approval. The N1 system is still under development and is not yet available for clinical use.
Key details
- $62 million Series B round led by DCVC, with participation from UC Investments, Skip Capital, Hostplus, and others.
- N1 platform aims to perform endovascular procedures robotically, either on-site, remotely, or autonomously.
- Remedy Robotics has partnered with over 100 hospitals worldwide for prototype deployments and clinical trials.
- The company conducted what it describes as the first fully remote neurointerventional procedures in October 2025 between two Toronto hospitals.
- N1 is designed for use in more than 30 cardiovascular conditions, including stroke and heart attack.
Why it matters
Hospitals and healthcare providers working with Remedy Robotics may gain access to new robotic tools for treating cardiovascular emergencies, potentially reaching patients in locations without on-site specialists. The funding enables Remedy to advance clinical trials and regulatory approval, which are required before the N1 system can be used in routine care. This could affect how quickly hospitals can adopt remote or autonomous intervention for stroke and other cardiovascular conditions, impacting patient access and treatment options.
